Hologic (HOLX) Announces Earnings Results, Beats Expectations By $0.05 EPS

Hologic (NASDAQ:HOLX) issued its quarterly earnings data on Thursday. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.05, Bloomberg Earnings reports. The firm had revenue of $791.10 million during the quarter, compared to analysts’ expectations of $785.80 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. Hologic’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.52 earnings per share. Hologic updated its Q2 guidance to $0.53-0.54 EPS.

Shares of Hologic (NASDAQ HOLX) traded down $1.65 on Thursday, hitting $38.80. 3,180,000 shares of the stock were exchanged, compared to its average volume of 2,480,000. The firm has a market capitalization of $10,700.00, a price-to-earnings ratio of 14.70, a P/E/G ratio of 1.89 and a beta of 0.77. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. Hologic has a 1-year low of $35.76 and a 1-year high of $46.80.

In other news, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $40.50, for a total transaction of $375,921.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by corporate insiders.

A number of equities research analysts recently issued reports on the stock. Cowen upgraded shares of Hologic to a “buy” rating and set a $52.00 price objective for the company in a report on Wednesday, December 20th. Deutsche Bank cut shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a report on Friday, January 19th. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Needham & Company LLC restated a “buy” rating and set a $50.00 price target on shares of Hologic in a report on Friday, November 3rd. Finally, Goldman Sachs Group upgraded shares of Hologic from a “buy” rating to a “conviction-buy” rating and upped their price target for the company from $45.00 to $50.00 in a report on Friday, December 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $48.79.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/08/hologic-holx-announces-earnings-results-beats-expectations-by-0-05-eps.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply